Beauty Health (NASDAQ:SKIN - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $63.88 million for the quarter. Beauty Health has set its Q1 2025 guidance at EPS and its FY 2025 guidance at EPS.
Beauty Health (NASDAQ:SKIN - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. Beauty Health had a negative net margin of 8.11% and a negative return on equity of 44.83%. The business had revenue of $83.50 million during the quarter, compared to analysts' expectations of $78.02 million. During the same quarter in the prior year, the company earned ($0.07) EPS. On average, analysts expect Beauty Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Beauty Health Trading Up 10.7 %
NASDAQ:SKIN traded up $0.11 on Friday, reaching $1.14. The company's stock had a trading volume of 218,752 shares, compared to its average volume of 1,074,069. The firm has a market cap of $142.78 million, a PE ratio of -2.71 and a beta of 0.84. Beauty Health has a 1-year low of $0.78 and a 1-year high of $3.63. The business's 50-day moving average price is $1.18 and its two-hundred day moving average price is $1.46. The company has a debt-to-equity ratio of 9.23, a quick ratio of 5.57 and a current ratio of 6.56.
Wall Street Analyst Weigh In
Separately, Canaccord Genuity Group cut their price target on Beauty Health from $1.75 to $1.50 and set a "hold" rating for the company in a report on Thursday, March 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $2.50.
Read Our Latest Research Report on Beauty Health
About Beauty Health
(
Get Free Report)
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.
Further Reading
Before you consider Beauty Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beauty Health wasn't on the list.
While Beauty Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
